NASDAQ$ASTH

Astrana Health Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Announced consolidated financial results, reflecting revenue growth and strategic investments

Apollo Medical Holdings, Inc. reported a strong third quarter with a 26% increase in total revenue and a 105% increase in net income attributable to ApolloMed. The company also raised its full-year 2021 guidance due to continued organic growth and increased risk pool settlements and incentives revenue.

  • Q3 total revenue increased by 26% year-over-year to $227.1 million.
  • Q3 net income attributable to ApolloMed increased by 105% year-over-year to $34.3 million.
  • Q3 earnings per share (diluted) increased by 64% year-over-year to $0.74.
  • Full-year 2021 guidance was raised due to organic growth and increased risk pool settlements.

Headline financials

Total Revenue

$227M

Previous: $180M+26.1%
EPS (adj)

$0.78

Previous: $0.46+69.6%
Capital Expenditures

-$16.4M

Previous: -$553K-2869.3%
Free Cash Flow

$17.9M

Previous: $16.2M+10.5%
Net Income

$34.3M

Previous: $16.7M+105.1%
Operating Income

$53.2M

Previous: $37.4M+42.3%
Gross Profit

-$152M

Previous: $58.3M-360.6%
Cash & Equivalents

$205M

Previous: $166M+23.3%
Total Assets

$871M

Previous: $814M+7.0%
Stock-Based Comp

$1.42M

Previous: $648K+119.1%

Revenue & EPS history

Astrana Health · Revenue · Quarterly

$227M

Q3 2021+26.1%vs Q3 2020
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

ApolloMed raised its full-year 2021 guidance for total revenue, net income, net income attributable to ApolloMed, EBITDA, and adjusted EBITDA.

Tailwinds

  • Total revenue is projected to be between $751.5 million and $758.5 million.
  • Net income is projected to be between $81.0 million and $83.5 million.
  • Net income attributable to ApolloMed is projected to be between $71.5 million and $73.5 million.
  • EBITDA is projected to be between $139.0 million and $143.0 million.
  • Adjusted EBITDA is projected to be between $168.5 million and $170.5 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

+0.7%

Avg return

Earnings day

-2.1%

Avg return

5 days after

+2.1%

Avg return

30 days after

40%

23 / 57 earnings

Positive

+83.3%

Q3 2011

Best reaction

-40.5%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+29.4%+22.5%+20.6%
Q3 2025-23.4%-29.4%-33.8%
Q1 2025-11.1%-20.8%-24.5%
Q4 2024-26.8%+5.0%+16.1%
Q3 2024-21.1%-27.9%-30.4%
Q2 2024-1.4%-1.8%+0.1%
Q1 2024-0.7%+1.5%+8.0%
Q4 2023+2.3%+1.8%-1.9%
Q3 2023+9.3%+2.9%+13.4%
Q2 2023+4.2%+3.5%-17.4%
Q1 2023+5.4%+7.0%-0.8%
Q4 2022+6.9%+5.2%+15.2%
Q3 2022+8.4%+8.9%-14.5%
Q2 2022-4.3%-11.0%-29.3%
Q1 2022-0.5%-5.4%-26.4%
Q4 2021-2.0%-11.0%-7.0%
Q3 2021+14.7%+30.5%+0.8%
Q2 2021-11.8%-10.7%-12.9%
Q1 2021+4.5%+4.7%+10.9%
Q4 2020+9.1%+8.8%+8.3%
Q3 2020-1.2%-1.6%+0.5%
Q2 2020+1.8%+2.4%+7.9%
Q1 2020-10.4%-11.6%+13.1%
Q4 2019-12.9%-24.0%+7.0%
Q3 2019-2.9%-0.9%+25.0%
Q2 2019-5.0%+4.8%+31.1%
Q1 2019-1.2%-4.3%-29.7%
Q4 2018-6.4%-8.3%-6.9%
Q3 2018+26.3%+4.0%-4.6%
Q2 2018-13.7%-23.3%-32.2%
Q4 2017+10.8%-6.3%+2.1%
Q1 2018+10.8%-6.3%+2.1%
Q3 2017+3.9%+3.9%+140.0%
Q2 2017+0.0%+0.0%-10.5%
Q1 2017+0.0%+6.7%+36.7%
Q1 2016+4.0%+4.0%+0.0%
Q3 2016-4.8%
Q2 2016-12.9%
Q1 2015-6.5%
Q3 2015-3.2%
Q2 2015+0.0%
Q2 2014+15.6%
Q4 2013
Q3 2013+1.6%
Q2 2013+13.5%
Q1 2013-13.3%
Q4 2012-2.2%
Q3 2012-9.1%
Q2 2012-40.5%
Q1 2012+0.0%
Q4 2011
Q3 2011+83.3%
Q2 2011+0.5%
Q1 2011-0.5%
Q4 2010-3.9%
Q3 2010+19.0%
Q2 2010+0.0%
Q1 2010-2.1%
Q4 2009+9.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro